Clinical studies
AROS has gained expertise and built an infrastructure that supports clinical studies. AROS is able to receive blood samples, isolate DNA/RNA, bank the samples for extended periods of time, analyze haplotypes/genotypes, identify gene signatures/pathways, and report this in a GLP / GCP compliant fashion usable for regulatory submissions.
AROS can perform this in a low cost, high throughput fashion.
Clinical Trials
AROS has expertise in genotyping responders / non-responders or slow / fast metabolizers based on SNP arrays, as well as identifying gene expression signatures that will identify responders / non-responders, or track patients with a high likelihood of side-effects. AROS offers identification of key pathways using bioinformatics tools that reflect drug action and side-effects on an individual patient basis.
AROS supports the customer from when the blood is drawn, to when the data is reported in a regulatory submission compliant format.
Thanks to high throughput robotics, AROS is able to handle thousands of samples in a short time frame.
Cancer
AROS scientists have many years of experience in cancer research, and a long and prestigious publication record in this area (see publications). AROS has performed multiple studies that include aspects such as;
• Laser microdissection of samples before isolation of DNA/RNA/miRNA
• PCR–based testing of microsatellite imbalance
• Identification of predictive signatures
• Identification of new drug targets
AROS has been able to supply large cohorts of patients based on its close relationship with the University Hospital of Aarhus (which owns part of the company), as well as other collaborators (this activity needs an ethical approval by local authorities).
Association studies using SNP arrays
In populations where properties are shared between groups of individuals, it is now possible to associate these properties to specific genotypes. AROS scientists have used this for the construction of haplotypes associated with diseases such as mental disorders, and for identification of genotypes related to reduced drug response.
Drug rescue
Some new drug candidates may unfortunately show a low response rate or unwanted side effects. AROS provides technologies such as massive global SNP genotyping and global expression monitoring, which can help identify the genotypes or signatures of the good responders, and reveal the nature of side effects. AROS has experience in these studies, and has participated in the rescue of several drug candidates, where mechanisms of action among similar compounds were identified, and also the triggering events leading to the side effects.